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Abstract
Non–small cell lung cancers (NSCLCs) are the leading
cause of cancer deaths in most developed countries.
Targeting heat shock protein 70 (Hsp70) expression
and function, together with the induction of lysosomal
membrane permeabilization (LMP), could overcome the
multiple anti–cell death mechanisms evidenced in
NSCLCs that are responsible for the failure of currently
used chemotherapeutic drugs. Because cardenolides
bind to the sodium pump, they affect multiple signaling
pathways and thus have a number of marked effects
on tumor cell behavior. The aim of the present study
was to characterize in vitro and in vivo the antitumor
effects of a new cardenolide (UNBS1450) on experi-
mental humanNSCLCs. UNBS1450 is a potent source of
in vivo antitumor activity in the case of paclitaxel-
and oxaliplatin-resistant subcutaneous human NCI-
H727 and orthotopic A549 xenografts in nude mice.
In vitro UNBS1450-mediated antitumor activity re-
sults from the induction of nonapoptotic cell death.
UNBS1450 mediates the decrease of Hsp70 at both
mRNA and protein levels, and this is at least partly
due to UNBS1450-induced downregulation of NFAT5/
TonEBP (a factor responsible for the transcriptional
control of Hsp70). These effects were paralleled by the
induction of LMP, as evidenced by acridine orange
staining and immunofluorescence analysis for ca-
thepsin B accumulation.
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Introduction
Non–small cell lung cancers (NSCLCs) are the leading
cause of cancer deaths in most developed countries and
have an overall 5-year survival rate of as low as 15% be-
cause adjuvant chemotherapy (including camptothecin,
taxane, platin, and vinca alkaloid derivatives) has only a lim-
ited therapeutic effect [1,2]. The successful treatment of
cancer with chemotherapy is largely dependent on the
ability of the treatment to trigger cell death in tumor cells.
Most tumor cells (including NSCLC cells) are naturally
resistant to not only apoptotic-related cell death [type I
programmed cell death (PCD)] but also non–apoptotic-related
types such as necrosis, autophagy (type II PCD), senescence,
mitotic catastrophe, and paraptosis [3–6]. NSCLCs are natu-
rally chemoresistant because they express a large set of
proteins (such as cyclooxygenase-2, prostaglandin E synthe-
tase, ornithine decarboxylase, lung-related resistance protein,
and glutathione S-transferases a, m, and k) that counteract
chemotherapeutic insults [7]. Resistance to cell death in
NSCLCs also relates to constitutive activation of the phospha-
tidylinositide 3-kinase [8], Akt [9,10], and NF-nB [10] signaling
pathways, all of which are interlinked [10,11].
In a previous study [12], we were able to demonstrate that a
cardenolide-related compound (UNBS1450) could constitute a
potential weapon against human experimental NSCLCs. Car-
denolides (e.g., ouabain and digitoxin) bind to the sodium pump
(i.e., Na+/K+ ATPase), which is an energy-transducing ion
pump that uses energy derived from the hydrolysis of ATP to
maintain a high K+ concentration and a low Na+ concentration
in the cytoplasm, which, in turn, provides the driving force for
the net movement of other substances such as glucose, amino
acids, Ca2+, and H+ [13–16]. Through their binding to the
sodium pump, cardenolides have a marked effect on tumor
cell behavior and affect several downstream signaling path-
ways, including those of Src kinases, epidermal growth factor
receptor (EGFR), Ras, p42/p44 mitogen-activated protein
kinases, and NF-nB [15,16]. UNBS1450 is able to deactivate
highly activated NF-nB pathways in A549 NSCLC cells by act-
ing simultaneously at several points along this pathway [12].
Indeed, the UNBS1450-induced deactivation of the NF-nB
pathways includes both the inhibitory I-nB portion of the
NF-nB signaling pathway and its stimulatory p65/Rel-A NF-nB
portion [12]. UNBS1450-induced effects at the inhibitory I-nB
protein level involve: 1) the upregulation of inhibitory protein
expression (as observed for I-nBb); 2) the downregulation of
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the phosphorylation levels of I-nBa; and 3) the downregulation
of the expression of cdc34 [12]. UNBS1450-induced effects
at the p65/Rel-A NF-nB level include: 1) the downregulation
of the expression levels of p65; 2) the downregulation of the
DNA-binding capacity of the p65 subunit; and 3) the down-
regulation of NF-nB transcriptional activity [12].
Polypeptides belonging to the heat shock protein 70
(Hsp70) major stress protein family interact with the NF-nB
multifunctional regulatory complex in cellular defense mech-
anisms [17]. In fact, with its ability to bind with a high level of
affinity to the plasma membrane, Hsp70 elicits rapid intra-
cellular calcium flux and activates NF-nB [18]. It has recently
been shown that Hsp70 and NF-kB are intimately linked in
the roles that they play in cancer cell migration [19,20]. One
of the anti–cell death mechanisms that is active in lung
cancer cells involves the overexpression of Hsp70 as it fulfills
its prosurvival function by inhibiting lysosomal membrane
permeabilization (LMP) [21,22]. Frese et al. [21] have shown
that the selective downregulation of Hsp70 induces mas-
sive caspase-independent tumor cell death in lung cancer,
but not in normal lung cells. Accumulating data now show
that lysosomes also function as death signal integrators that
mediate caspase-independent and/or apoptosis-inducing
factor– independent PCD (for a review, see Jaattela [23]
and Fehrenbacher and Jaattela [24]).
The aim of the present study was to pursue our previous
investigations [12] into the in vitro and in vivo antitumor
effects of UNBS1450, a hemisynthetic derivative of 2W-oxo-
voruscharin (UNBS1244; Figure 1) [25], in the case of human
NSCLC models. In this study, we focus on UNBS1450-
mediated effects on Hsp70 expression and LMP-related
cell death.
Materials and Methods
Compounds
The drugs used were as follows: ouabain (Acros Organ-
ics, Geel, Belgium), digitoxin (Acros Organics), paclitaxel
(Taxol; S. A. Bristol-Myers Squibb, Brussels, Belgium), irino-
tecan (Campto; Aventis, Brussels, Belgium), SN-38 (7-ethyl-
10-hydroxycamptothecin; Aventis), oxaliplatin (Oxaliplatin;
Inter-Chemical Ltd., ShenZhen, China), cisplatin (Platinol;
S. A. Bristol-Myers Squibb), and carboplatin (Paraplatin; S.
A. Bristol-Myers Squibb). As detailed elsewhere [25],
UNBS1244 was chemically extracted from the bark of
Calotropis procera, an African plant. C. procera specimens
were provided by Prof. Pierre Guissou (Laboratory of Toxi-
cology, University of Ouagadougou, Ouagadougou, Burkina
Faso). UNBS1450 was obtained from UNBS1244 by hemi-
synthesis at the laboratory facility of Unibioscreen SA (Brus-
sels, Belgium) (Figure 1) [25].
Cell Lines
The A549 (code CCL-185) and A427 (code HTB-53) cell
lines were obtained from the American Type Culture Collec-
tion (Manassas, VA) and were maintained in minimum es-
sential medium (MEM) supplemented with 5% fetal bovine
serum. CAL-12T cells, which were obtained from the DSMZ
Animal Cell Line Database (code ACC-443; DSMZ, Bruns-
wick, Germany), were maintained in OptiMEM medium sup-
plemented with 5% fetal bovine serum. NCI-H727 cells were
obtained from the European Collection of Cell Cultures (code
ECACC 94060303; Sigma-Aldrich, Bornem, Belgium) and
were maintained in RPMI medium supplemented with 10%
fetal bovine serum. All media were supplemented with a
mixture of 0.6 mg/ml glutamine (GibcoBRL/Invitrogen SA,
Merelbeke, Belgium), 200 IU/ml penicillin (GibcoBRL),
200 IU/ml streptomycin (GibcoBRL), and 0.1 mg/ml genta-
mycin (GibcoBRL). Trypsin–EDTA, fetal bovine serum, cell
culture media, and their supplements were obtained from
GibcoBRL/Invitrogen SA. Fetal bovine serum was heat-
inactivated for 1 hour at 56jC. All cells were incubated in a
5% CO2 atmosphere at 37jC in sealed (air-tight) Falcon
plastic dishes (Nunc/Invitrogen SA, Merelbeke, Belgium).
In Vitro Overall Growth Determination
Overall cell growth was assessed by 3-[4,5-dimethyl-
thiazol-2yl]-diphenyltetrazolium bromide (MTT) (Sigma, Bor-
nem, Belgium) colorimetric assay, as detailed elsewhere
[26]. The tumor cells were incubated for 72 hours in the
presence (or in the absence; control) of various drugs at
concentrations ranging between 109 and 105 M (with
semi-log concentration increase). The experiments were
carried out in sextuplicate.
Flow Cytometry Analyses for Determining Apoptotic-Related
Versus Non–Apoptotic-Related Cell Death and Cell
Cycle Kinetics
Flow cytometry analyses of apoptotic-related versus
non–apoptotic-related cell death were performed according
to the experimental protocol detailed by Darzynkiewicz et al.
[27]. Briefly, after various treatments with UNBS1450
(Figure 4, A and B), the cells were incubated in darkness
in Annexin V–FITC (V)–propidium iodide (PI) solution for
15 minutes at 4jC (Annexin V–FITC kit; Immunotech,
Marseilles, France). Data from around 10,000 cells were
Figure 1. Chemical structures of UNBS1244 and its hemisynthetic derivative,
UNBS1450. The manner in which UNBS1244 was identified in the African
plant C. procera and the hemisynthesis of UNBS1450 from UNBS1244 are
described in detail in Van Quaquebeke et al. [25].
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recorded on a logarithmic scale for each sample. XL System
II (Beckman Coulter, Miami, FL) was used to give a precise
definition of both the percentage of cells in the apoptotic and/
or nonapoptotic compartments and the percentage of normal
cells (i.e., those apparently left unaffected by UNBS1450
treatment). The so-called normal cells were negative for both
Annexin V and PI staining, whereas the apoptotic cells were
positive for Annexin V but were negative for PI. The non-
apoptotic cells (whose cell membranes have holes) were
positive for both PI and Annexin V [23]. Each experiment was
carried out in triplicate. Additional experiments aiming to rule
out UNBS1450-induced apoptotic effects on human A549
NSCLC cells were carried out by the terminal deoxynucleo-
tidyl transferase deoxyuridine triphosphate nick-end labeling
(TUNEL) technique, using an experimental protocol detailed
elsewhere [28]. Briefly, A549 cells were treated for 72 hours
with UNBS1450 at a concentration of 10 nM or were incu-
bated with the solvent alone. As positive control for apop-
tosis, A549 cells were incubated for 72 hours with 2.5 mM
doxorubicin. Apoptosis was assessed by a flow cytometry–
based TUNEL assay. At indicated time points, both non-
adherent and adherent cells were harvested and pooled,
and fixed overnight (15 hours) with 1% paraformaldehyde
(1 hours) and 70% ethanol. On the next day, the cells were
processed using APO-BRDU kit (Sigma-Aldrich), according
to the manufacturer’s instructions. Analysis was performed
immediately after the staining reaction on an Epics XL MCL
flow cytometer (Beckman Coulter) equipped with a 488-nm
argon laser. Apoptosis was quantified by following the in-
crease in FITC dUTP labeling, as against control cells
(solvent alone).
The cell cycle kinetics of A549 cells, either treated with
UNBS1450 or left untreated (Figure 4F ), was determined by
flow cytometry analyses of PI nuclear staining, using a pre-
viously detailed methodology [29].
Flow Cytometry Analyses for Acridine Orange Staining
Acridine orange staining was carried out as an indicator of
lysosomal leakage, as described by Nylandsted et al. [22].
Immunofluorescence Analyses for Cathepsin B Expression
As an indicator of lysosomal leakage, cathepsin B immuno-
staining was carried out using the monoclonal anti–cathepsin
B antibody (1:50) provided by Oncogene Research/VWR
International (Leuven, Belgium). Human A549 NSCLC cells
were fixed and permeabilized as described by Nylandsted
et al. [22]. Immunoflourescence analyses were performed in
this study as detailed by Mathieu [30].
Total RNA Extraction
Total RNA from the A549 cell line was prepared using
the TRIzol isolation reagent (GibcoBRL/Life Technologies/
Invitrogen SA, Merelbeke, Belgium), according to the manu-
facturer’s instructions. The RNA extracted was treated with
DNase I (GibcoBRL/Life Technologies/Invitrogen SA) to elim-
inate any remaining genomic DNA. The quantity of RNA was
measured by spectrophotometric analysis at 260 nm (Beck-
man Coulter DU 640; Analis, Ghent, Belgium). The quality
and the integrity of the extracted RNA were assessed both
by BioAnalyser 2100 (Agilent, Toulouse, France) and by gel
electrophoresis in 1% agarose TAE gels (Invitrogen SA), and
were visualized by ethidium bromide staining under UV light.
Northern Blot Analyses for Hsp70
Ten micrograms of RNA samples was denatured in 100%
formamide. Glyoxal (0.7 M, final concentration) and bromo-
phenol blue were added to the samples, which were then
heated at 65jC for 10 minutes, after which they were sub-
jected to electrophoresis in a 1.2% agarose dissolved in Tris/
acetate, an EDTA buffer. Electrophoresis was performed at
80 V (4 V/cm) for 120 minutes. Transfer to a nylon mem-
brane (Hybond-N+; Amersham Pharmacia Biotech Benelux,
Roosendaal, The Netherlands) was accomplished electro-
phoretically, and the RNA was cross-linked by UV irradiation.
Blots were hybridized with a DNA probe generated by
polymerase chain reaction. The Hsp70 fragment was pro-
duced by a standard reverse transcription–polymerase
chain reaction using the primers provided by Life Technolo-
gies/Invitrogen SA. These primers were selected using
HYBSIMULATOR software (Advanced Gene Computing
Technology, Irvine, CA). The primers were 5V-TTGAGGG-
CATCGACTTC-3V (forward) and 5V-CTCGTACACCTGGAT-
CAG-3V (reverse). The 470-bp fragment so generated was
purified using the High Pure PCR Product Purification Kit
(Roche Diagnostics, Mannheim, Germany), in accordance
with themanufacturer’s instructions. The probewas generated
by a radiolabeling process using random primer technique, in
conjunction with a commercially available kit (Rediprime II;
Amersham Pharmacia Biotech Benelux), in the presence of
[a-32P] dCTP (Amersham Pharmacia Biotech Benelux). The
probe was purified using a QuickSpin DNA Sephadex column
(Roche Diagnostics), and the rate of incorporation was quan-
tified by scintillation counting. The membrane was sub-
sequently hybridized overnight at 65jC (Rapid-hyb Solution;
Amersham Pharmacia Biotech Benelux). After stringent
washing, the hybridization results were visualized using a
Fuji-BAS5000 scanner and an AIDA image analyzer software
(Raytest Benelux, Tilburg, The Netherlands).
Western Blot Analyses
Cell extracts were prepared by directly lysing sub-
confluent A549 cells in a boiling lysis buffer (10 mM Tris,
pH 7.4; 1 mM Na3O4V; 1% sodium dodecyl sulfate, pH 7.4).
Forty micrograms of proteins (evaluated by bicinchoninic acid
(BCA) protein assay; Pierce/PerbioScience, Erembodegem,
Belgium) was loaded onto a denaturing polyacrylamide gel.
Following electrophoresis, the proteins were blotted onto a
Polyscreen*PVDF membrane (NEN; Life Science Products,
Boston, MA). The proteins of interest were immunodetected
by specific affinity-purified primary antibodies (in Tris-buffered
saline (TBS) containing 0.1% Tween-20 and 5% fat-free dry
milk powder or bovine serum albumin), in conjunction with a
secondary antibody in the shape of immunoglobulin (Ig) G
conjugated with horseradish peroxidase. Control experiments
included the omission of the incubation step with the primary
antibodies (negative control). Equal loading was verified by
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the bright red coloration of the membranes. The integrity
and the quantity of the extracts were assessed by tubulin
immunoblotting. The primary antibodies were: 1) Hsp70
(1:500) (CST Technologies, Westburg, Leusden, The Nether-
lands); 2) tubulin (1:3000) (AbCam, Cambridge, UK); and 3)
poly(ADP-ribose) polymerase (PARP; 1:250) (BD PharMin-
gen, Erembodegem, Belgium). The secondary antibodies
used were as follows: antimouse and antirabbit IgG (Pierce/
PerbioScience) and antirat (AbCam). The blots were devel-
oped using the Pierce Supersignal Chemiluminescence sys-
tem (PerbioScience).
Measurements of UNBS1450-Induced Effects on Sodium
Pump Activity
Porcine cerebral cortex sodium potassium ATPase ac-
tivity was measured using an enzyme-linked assay in which
the formation of ADP by ATPase was coupled to NADH
oxidation in the presence of the enzymes pyruvate kinase
and lactate dehydrogenase, with the intermediate substrate
phosphoenolpyruvate present in excess [25]. The samples
(3  103 U of porcine Na+/K+ ATPase; Sigma-Aldrich) were
preincubated for 30 minutes at 37jC in 30 mM Tris–HCl
(pH 7.4) and 5 mM MgCl2, with increasing inhibitor con-
centrations. The reaction was then initiated by the addition of
1 ml of a reaction mixture, which contained (in mM or ap-
propriate units): Tris–HCl (pH 7.4), 30; NaCl, 100; KCl, 5;
MgCl2, 5; ATP (Sigma-Aldrich), 3; PEP (Calbiochem/VWR
International, Leuven, Belgium), 1; NADH (Calbiochem), 0.3;
EGTA (Sigma-Aldrich), 0.1; lactate dehydrogenase (Sigma-
Aldrich), 5; and pyruvate kinase (Sigma-Aldrich), 6, with
corresponding inhibitor concentrations. Absorbance was
measured at 340 nm after 1-hour incubation at 37jC in a
1-ml cuvette (VWR International). The procedure was char-
acterized using an inhibitor range from 1 to 50,000 nM
UNBS1450, ouabain, and digitoxin.
In Vivo Subcutaneous Grafting of NCI-H727 and Orthotopic
Grafting of Human A549 NSCLC Cells
Potential in vivo UNBS1450-related therapeutic effects
were determined in nude mice with human NCI-H727
subcutaneous xenografts or A549 orthotopic xenografts
by chronic (12 times) intraperitoneal administration of
UNBS1450 thrice a week, for four consecutive weeks. The
maximum tolerated dose (MTD) for UNBS1450 (and for
the other compounds under study) was determined by ad-
ministering it acutely (in one single intraperitoneal dose) to
healthy animals (not grafted with tumors). The survival pe-
riods and the weights of the animals were recorded for up to
28 days after the injection of the compound. Eight different
doses of UNBS1450 (i.e., 2.5, 5, 10, 20, 40, 80, 120, and
160 mg/kg) were used for the determination of the MTD
index. The MTD index is defined as the concentration that
kills at least onemouse in a group of three after a minimum of
28 days. The acute MTD for UNBS1450 through the intra-
peritoneal route was 120 mg/kg (for the MTDs of all com-
pounds used in this study, refer to Figure 2A).
Subcutaneous NCI-H727 xenografts were realized by
grafting 2  106 human NCI-H727 cells onto the left flank
of 8-week-old female nu/nu mice (weight, 21–23 g; Bio-
Services, Uden, The Netherlands). Tumor size was measured
as previously described [31] (i.e., twice weekly, using a cali-
per) and is expressed in areas (mm2) by multiplying the two
largest perpendicular diameters. Based on this, we were able
to evaluate potential UNBS1450-induced decreases in tumor
growth rates (i.e., drug-induced tumor surface inhibition).
Orthotopic A549 xenografts were obtained by grafting 2
106 human A549 cells through the thorax into the left-hand
side of the lungs of the nude mice (see NCI-H727 xeno-
grafts), as detailed elsewhere [7]. All orthotopic grafts were
performed under anesthesia [saline, Rompun (Bayer, Lever-
kusen, Germany), and Imalgene (Merial, Lyons, France),
5:1:1, vol/vol/vol]. Highly reproducible tumor developments
(100%) were obtained for both NCI-H727 and A549 tumor
grafts in each experiment.
For ethical reasons, the endpoint of the NCI-H727–
related experiments was the sacrifice (in a CO2 atmosphere)
of all subcutaneous xenograft-bearing nude mice on the 49th
day after tumor graft because the mean tumor size had
reached 500 mm2 in the control group. The endpoint of the
A549-related experiments was the recording of the survival
period of each of the A549 NSCLC–bearing nude mice. For
ethical reasons, each animal was submitted to euthanasia (in
a CO2 atmosphere) when it had lost 20% of its weight taken
at the time of the tumor graft. As detailed elsewhere, autopsy
and histology were performed on each mouse to confirm the
presence of tumor development [7]. All in vivo experiments
described in the current study were performed based on
authorization no. LA1230509 of the Animal Ethics Commit-
tee of the Belgian Federal Department of Health, Nutritional
Safety, and the Environment.
Statistical Analyses
Statistical comparisons between the control group and
the treated group were performed by first carrying out the
Kruskal-Wallis test (a nonparametric one-way analysis of
variance) and, where this test revealed significant differ-
ences, we investigated whether any of the groups treated
differed from controls. For this purpose, we applied the
Dunn’s multiple comparison procedure (two-sided test),
which was adapted to the comparison of treatments and
controls [i.e., where only (k  1) comparisons were carried
out among the k groups tested by the Kruskal-Wallis test,
instead of the possible k(k  1)/2 comparisons considered in
the general procedure]. Survival analysis was carried out
using Kaplan–Meier curves and the Gehan generalized
Wilcoxon test. All statistical analyses were carried out using
Statistica software (Statsoft, Tulsa, OK).
Results
UNBS1450 Is a Cardenolide with Marked In Vitro Antitumor
Activities in the Case of Human NSCLC Cell Lines
UNBS1244 is a novel cardenolide that we identified in
African specimens of C. procera [25]. UNBS1450, which is
a hemisynthetic derivative of UNBS1244 [25], differs from
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well-known cardenolides, such as ouabain and digitoxin, at
the molecular level in terms of several characteristics: 1) its
sugar moiety is linked twice to the steroid backbone, where-
as ouabain and digitoxin are linked only once; 2) the molec-
ular structure of the sugar moiety of UNBS1244 differs from
those of ouabain and digitoxin because of the presence of
a thiazolidinone at the 3V end of the sugar moiety; and 3) the
A/B cyclic junction is cis for ouabain and digitoxin, whereas
it is trans for UNBS1244 (Figure 1). UNBS1450 differs from
UNBS1244 by one chemical substituent only, namely, the
hydroxyl in position 19 of the steroid skeleton in UNBS1450
compared to the formyl in the same position in UNBS1244
(Figure 1). Although this chemical modification led to a
significant decrease in the in vivo toxicity of UNBS1450 com-
pared to that of UNBS1244 (Figure 2A, bottom, MTD values),
it nevertheless maintained the in vitro level of the antitumor
activity of UNBS1450 compared to that of UNBS1244 (Fig-
ure 2A). However, it should be emphasized that poor solu-
bility might lead to the precipitation of compounds in vivo and
to an overestimated MTD. Solubility analyses revealed that
UNBS1450 is four times more soluble than UNBS1244 in a
DMSO (10%)/H2O (90%) solution and is even more soluble
than UNBS1244 in an ethanol (40%)/polyethylene glycol
(40%)/H2O (20%) solution. We are currently performing pre-
formulation studies to arrive at the best way possible to
solubilize UNBS1450 for in vivo experiments.
The data in Figure 2A indicate that, in four different
NSCLC cell lines in vitro, UNBS1244 and UNBS1450 ex-
hibited IC50 values similar to those for ouabain, digitoxin,
and paclitaxel, whereas SN-38 (the active metabolite of
Ct
UNBS1450: 20mg/kg
UNBS1450: 10mg/kg
p = 0.003
p = 0.009
Figure 2. In vitro and in vivo UNBS1450-mediated antitumor effects. (A) In vitro antitumor effects contributed by four cardenolides (UNBS1450, UNBS1244,
ouabain, and digitoxin) relative to the four human NSCLC cell lines A549 (open bars), A427 (hatched bars), CAL-12T (gray bars), and NCI-H727 (black bars), in
comparison with the five anticancer drugs already assayed against NSCLCs [i.e., paclitaxel, SN-38 (the active metabolite of irinotecan), cisplatin, oxaliplatin, and
carboplatin]. The drugs (X axis) were assayed at nine concentrations ranging from 109 to 105 M, with semi-log concentration increases; each concentration was
analyzed six times. The results are presented as IC50 values (the Y axis in logarithmic values) representing the concentrations at which each compound reduced
the overall growth rate of the cell lines by 50% after 3 days of treatment. The MTD for each compound is given at the bottom of (A). MTDs are expressed in
milligrams per kilogram following a single intraperitoneal administration (except for paclitaxel, which was given as a single intravenous administration) to healthy
mice. Note that SN-38 (*) was tested in vitro only. (B and C) Illustration of in vivo–mediated UNBS1450 effects on the tumor growth rates of NCI-H727 NSCLC
subcutaneous xenografts (B) and on the survival periods of A549 NSCLC orthotopic xenograft –bearing mice (C). Also illustrated are paclitaxel-mediated (7.5 mg/
kg; open dots; B) and oxaliplatin-mediated (10 mg/kg; crosses; B) effects on NCI-H727 xenograft growth rates (B). Paclitaxel was assayed intravenously (B),
whereas oxaliplatin (B) and UNBS1450 (B and C) were assayed intraperitoneally. All compounds were injected thrice a week (on Mondays, Wednesdays, and
Fridays) for four consecutive weeks, with the first treatment starting on the 14th day after tumor graft. The control mice that received the vehicle are symbolized by
black dots. Each experimental group consisted of nine mice. (D) The effects of UNBS1450 on mouse body weight as a check on UNBS1450-associated toxic side
effects. UNBS1450 was injected intraperitoneally into A549 NSCLC orthotopic xenograft –bearing mice thrice a week (on Mondays, Wednesdays, and Fridays) for
four consecutive weeks. The treatment started on the 14th day after tumor graft. The control mice that received the vehicle are symbolized by black dots. Each
experimental group consisted of nine mice. The administration schedules are the same for tumor growth rates (B), animal survival (C), and weight monitoring (D).
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irinotecan) appeared to be less active. The three platin deri-
vatives were actually less active in vitro than the remaining
compounds under study (Figure 2A).
UNBS1450 Induces Significant In Vivo Antitumor Activity
in Relation to Human NSCLC Xenografts
WhereasUNBS1450 significantly (P < .01, on the 49th day
after tumor graft) decreased the tumor growth rate in the
subcutaneous NCI-H727 xenograft model, paclitaxel and
oxaliplatin did not (Figure 2B). Twelve intraperitoneal admin-
istrations of 10 mg/kg UNBS1450 led to a similar level of
antitumor activity as 12 intraperitoneal administrations of
20 mg/kg (for a precise experimental schedule, refer to
Figure 2B). UNBS1450 also significantly increased the sur-
vival periods of human A549 orthotopic NSCLC xenograft–
bearing mice (Figure 2C) treated with 10- or 20-mg/kg dose
schedules; no statistically significant (P > .05) differences
were observed between the curves obtained with a 10-mg/kg
dose schedule and the curves obtained with a 20-mg/kg
dose schedule (Figure 2C). In contrast, we reported pre-
viously that 12 administrations of 5 mg/kg UNBS1450 (com-
pared to 10 and 20 mg/kg) induced weaker (but nevertheless
statistically significant; P < .05) therapeutic effects [12].
When administered per os, UNBS1450 was also able to
bring about a beneficial therapeutic effect in the case of the
orthotopic A549 model [12]. With respect to the reference
compounds used to treat NSCLC patients, only irinotecan
tended (P = .06) in the direction of an increase in the sur-
vival periods of human A549 orthotopic NSCLC xenograft–
bearing mice, as previously reported in Mathieu et al. [7]. We
previously showed that intraperitoneal/intravenous adminis-
tration of paclitaxel and intraperitoneal administration of
oxaliplatin do not offer any significant therapeutic effect in
the case of A549 NSCLC model [7], a phenomenon also
observed in the present study.
We monitored the weights of the A549 NSCLC orthotopic
xenograft–bearing mice to assess the toxic side effects
associated with chronic UNBS1450 treatment of tumor-
bearing mice. Figure 2D shows that chronic treatment
(12 intraperitoneal administrations) with 10 or 20 mg/kg
UNBS1450 did not significantly modify the weight profile
evolution of the mice bearing the A549 xenografts, thus sug-
gesting that UNBS1450 did not produce any major toxic ef-
fects at the dose range of 10–20mg/kg—the same ones that
offer actual antitumor effects (Figure 2, B and C).
UNBS1450-Induced Antitumor Effects Relate to Its
Inhibitory Effects on Na+/K+ ATPase Activity
For Na+/K+ ATPase activity assay, we used a purified
cerebral cortex porcine Na+/K+ ATPase because of the great
similarity between the porcine a1 subunit and the human a1
subunit (amino acid sequence alignments indicate a 99%
similarity between these two proteins). Figure 3 clearly shows
that UNBS1450 has a greater inhibitory effect on sodium
pump activity than ouabain or digitoxin. The IC50 values of
UNBS1450, ouabain, and digitoxin in terms of the inhibition
of sodium pump activity (Figure 3) are in the same ranges
as the IC50 values obtained in terms of antiproliferative ef-
fects (Figure 2A). These data therefore suggest that the
UNBS1450-related antitumor effects detailed in the present
study are at least partly related to UNBS1450-induced inhi-
bition of sodium pump activity.
UNBS1450 Causes a Time-Dependent and
Dose-Dependent Increase in Non–Apoptotic-Related
A549 Cell Death
Although the number of cardenolides has been reported
as inducing apoptosis (in micromolar dose ranges) in human
prostate cancer cells [32–36], we did not observe any such
features with UNBS1450 (in nanomolar dose ranges, cor-
responding to IC50) in the case of human A549 NSCLC cells
(Figures 4, A–E ) nor, indeed, in that of NCI-H727 cells (data
not shown). We used flow cytometry analysis to monitor the
effect of 1, 10, and 100 nM UNBS1450 on A549 cell death
over 24 and 72 hours (Figure 4, A and B). PARP cleavage
analysis (10 and 100 nM UNBS1450 in Figure 4, C and D,
respectively) only revealed the presence of intact (un-
cleaved) PARP (molecular mass, 116 kDa), whereas frag-
ments representative of apoptosis (83–89 kDa) and necrosis
(50–60 kDa) were absent. In fact, 10- and 100-nM doses of
UNBS1450 caused a time- and dose-dependent increase in
non–apoptotic-related A549 cell death (Figure 4, A and B)—
a feature observed in the case of NCI-H727 NSCLC cells
(data not shown). We decided to work with nanomolar, in-
stead of micromolar, doses of UNBS1450 because the IC50
window for UNBS1450 in the antiproliferative assay is in the
nanomolar range (Figure 2A). To offer the ultimate experi-
mental proof of the fact that UNBS1450 does not induce
apoptosis in A549 NSCLC cells, we also performed TUNEL
analysis because positive staining for both PI and Annexin
V may occur late in the process, leading to apoptotic cell
death in some instances. The data illustrated in Figure 4E
once more indicate that UNBS1450 does not induce any
apoptotic feature in A549 NSCLC cells.
Figure 3. UNBS1450 inhibits Na+/K+ ATPase activity. The effects of
UNBS1450, ouabain, and digitoxin on sodium pump activity were charac-
terized by the use of the purified porcine cerebral cortex Na+/K+ ATPase. The
activity of the porcine sodium pump in the absence of cardiotonic steroids
was arbitrarily normalized to 100% ( Y axis). Concentrations ranging from 1
to 10,000 nM were analyzed (X axis). Each concentration was analyzed
in sextuplicate.
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UNBS1450 Induces Cell Cycle Arrest in S Phase
In addition to the data already contributed by the MTT
colorimetric assay (Figure 2A), we used a flow cytometry
approach to characterize the antiproliferative effects ob-
served with UNBS1450 (Figure 4F ). The data in Figure 4F
show that 10 nM UNBS1450 markedly increased the per-
centage of A549 cells in the S phase of the cell cycle and, to a
lesser extent, in the G2 phase.
UNBS1450 Induces Vacuolization-Related Cell Death
in A549 Tumor Cells
The flow cytometry–related analyses detailed in Figure 4,
A and B; the PARP analyses in Figure 4, C and D; and the
TUNNEL analysis in Figure 4E show that UNBS1450-
mediated cell death occurs through a non–apoptotic-related
cell death process. Computer-assisted videomicroscopy
analysis further revealed that UNBS1450 did not kill the
A549 NSCLC cells by osmotic shock (data not shown). In
addition, this analysis strongly suggests that UNBS1450
did not induce necrotic-related A549 cell death (data not
shown)—an assertion corroborated by the fact that PI
heavily stained the A549 cell nuclei, a feature observed
during flow cytometry analyses for apoptotic measurements
(Figure 4, A and B). When dying cells still stain heavily with
PI, necrotic processes are unlikely to occur [3,5]. Two
additional arguments in favor of the finding that UNBS1450
does not induce necrotic-related cell death are as follows:
firstly, in vivo, UNBS1450 did not increase the proportion
of necrotic areas in the NCI-H727 and A549 xenografts
(data not shown); secondly, UNBS1450 treatment did not
Figure 4. UNBS1450 causes a time- and dose-dependent increase in non–apoptotic-related A549 cell death. Characterization of UNBS1450-induced effects with
respect to the level of cell death (monitored by flow cytometry) over 24 hours (A) and 72 hours (B); the open bars represent normal cells, whereas the black and
gray bars represent apoptotic and nonapoptotic cells, respectively. (C and D) Effects of 10 and 100 nM UNBS1450 over a period of 20 hours on the cleavage
pattern of PARP; intact (uncleaved) PARP has a molecular mass of 116 kDa. (E) TUNEL analyses were performed to confirm the absence of UNBS1450-induced
apoptosis in A549 NSCLC cells. A549 cells were incubated for 72 hours in the presence of 2.5 M doxorubicin (positive control) or 10 nM UNBS1450. Control cells
were incubated with the solvent alone. The percentage of TUNEL-positive cells in each condition is reported. (F) The cell cycle kinetics was monitored by flow
cytometry over 72 hours; the open bars represent the proportion of A549 cells in the G1 phase of their cell cycles, whereas the gray and black bars represent the
proportion of A549 cells in the S and G2 phases, respectively. Each experiment was carried out in triplicate, and panels A, B, and F illustrate the net results obtained
after the combination of triplicates. (G and H) Illustration of marked cytoplasmic vacuole formation (indicated by white arrows) in A549 NSCLC cells over a 24-hour
period of UNBS1450 treatment. White bars represent 15 m. The magnification is the same in (G) and (H).
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bring about a PARP cleavage that yielded fragments of 50 to
62 kDa (specific for necrosis features), as shown in Figure 4,
C and D. Thus, UNBS1450 does not seem to induce either
apoptotic-related or necrotic-related cell death in A549
NSCLC cells, but rather a cell death process associated with
a dramatic cytoplasmic vacuolization revealed by computer-
assisted videomicroscopy (Figure 4, G and H ).
UNBS1450 Induces Hsp70 Downregulation
One of the anti–cell death mechanisms active in lung
cancer cells involves the overexpression of Hsp70 [21],
which fulfills its prosurvival function by inhibiting LMP [22].
Nylandsted et al. [37] have reported that the abrogation of
Hsp70 synthesis by the adenoviral transfer of a fragment
of Hsp70 cDNA resulted in extensive cell death in several
breast cancer cell lines, and that this cell death–associated
effect is clearly different from the standard apoptosis path-
way. Frese et al. [21] have shown that selective down-
regulation of Hsp70 induces massive caspase-independent
tumor cell death in lung cancer, but not in normal lung cells.
Hsp70 is under the transcriptional control of the activator,
NFAT5/TonEBP [38]. Its activity is affected by Na+/K+ bal-
ance, and its downregulation by ouabain has already been
evidenced [39]. As revealed byWestern blot analyses, 10 nM
UNBS1450 decreases NFAT5 protein levels (Figure 5A).
This effect leads to a decrease of the Hsp70 both at the
mRNA level (as revealed by Northern blot analyses; Fig-
ure 5B) and at the protein level (as revealed by Western blot
analyses; 10 and 100 nM, in Figure 5, C and D, respectively).
UNBS1450 Induces LMP-Mediated Cell Death
As indicated above, Hsp70 fulfils its prosurvival function
by inhibiting LMP [22]. Recent data indicate that lysosomes
also function as death signal integrators that mediate
caspase-independent and/or apoptosis-inducing factor–
independent PCD [23,24]. The permeabilization of lyso-
somes was analyzed by measuring the emission of green
fluorescence, which is indicative of the leakage of acridine
orange from the acidic compartment to the cytosol, as de-
scribed by Nylandsted et al. [22]. In this experiment, cells
were stained with acridine orange and either left untreated
or treated with 10 nM UNBS1450 for 15 hours. As shown in
Figure 6, UNBS1450 treatment induced amarked increase in
green fluorescence, and we demonstrated the influence of
UNBS1450 on lysosomal permeabilization. Furthermore, im-
munofluorescent staining for cathepsin B (Figure 7) showed
a distinct pattern for untreated cells (concentrated, punc-
tuated staining; Figure 7B), in comparison with UNBS1450-
treated cells with diffuse cathepsin B staining (Figure 7D), and
thus revealed leakage of lysosomes.
Discussion
Apart from their well-known effects in congestive heart failure
[13], cardenolides have also been reported as having potent
anti-inflammatory [40,41] and antitumor [42–44] effects,
especially on human prostate [32–35] and breast [14,45]
cancers. Xenavex, an ethanolic botanical extract compound
Figure 5. UNBS1450 induces Hsp70 downregulation. (A) Characterization (Western blot analyses) of NFAT5/TonEBP protein accumulation in untreated and
UNBS1450-treated (10 nM) A549 cells. (B) Determination (Northern blot analyses) of 10, 100, and 1000 nM UNBS1450-mediated effects on Hsp70 mRNA
accumulation over a period of 9 hours (lower panel). (C and D) Effects of 10 and 100 nM UNBS1450 treatment on the accumulation of Hsp70 in A549 tumor cells.
Figure 6. UNBS1450 induces LMP in human A549 NSCLC cells. UNBS1450-
induced permeabilization of lysosomes, as analyzed by measuring the
emission of green fluorescence (flow cytometry), which is indicative of the
leakage of acridine orange from the acidic compartment to the cytosol. The Y
axis represents the number of counted events (cells), whereas the X axis
represents green fluorescence intensity (in logarithmic scale).
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of various cardioglycosides (with an enriched fraction of
oleandrin) derived from Nerium oleander, is entering a mul-
ticenter phase I/II clinical trial program as a potential mono-
therapy for NSCLC (for details, see http://clinicaltrial.gov).
Both the data from the present study and those that we
reported previously [12,25] introduce UNBS1450, a novel
cardenolide (Figure 1), as a novel anticancer drug with real
potential for the treatment of NSCLCs. Indeed, both the data
from the present study and the data from previous studies
[12,25] clearly indicate that UNBS1450 has a number of
marked antitumor effects, both in vitro and in vivo, on various
aggressive models of human NSCLCs.
In a previous study [12], we observed that some of the
NSCLC antitumor effects induced by UNBS1450 are linked
to the inactivation of the NF-nB pathway. As indicated in the
Introduction, the NF-kB and Hsp70 pathways are intimately
related [17–20]; in the present study, we therefore focused
our attention on a specific target for UNBS1450 in the shape
of Hsp70. One of the anti–cell death mechanisms active in
lung cancer cells involves the overexpression of Hsp70. Its
high level of expression in various human tumors correlates
with resistance to therapy and poor prognosis [21,46,47].
Nylandsted et al. [48] have demonstrated that the loco-
regional application of an adenovirus expressing antisense
Hsp70 cDNA (AdasHsp70) eradicates orthotopic xenografts
of glioblastomas and breast carcinomas, and subcutaneous
xenografts of colon carcinomas in immunodeficient mice.
Moreover, Frese et al. [21] have shown that selective down-
regulation of Hsp70 induces cell death in lung cancer, but not
in normal lung cells. The depletion of Hsp70 is therefore an
effective means of combating cancer. However, its down-
regulation by adenoviral transfer is quite unsuitable for
clinical application in humans. We show here that the novel
anticancer drug UNBS1450 decreases the levels of both
Hsp70 mRNA and protein, and thus could be used more
efficiently for anti-Hsp70–based therapy. The transcriptional
control of Hsp70 involves the transcriptional activator,
NFAT5/TonEBP [38]. We also show that UNBS1450 de-
creases the level of expression of NFAT5/TonEBP in A549
tumor cells. Similar in vitro effects have previously been
reported for another cardenolide (ouabain) in Madin-Darby
canine kidney cells [39]. However, in the study reported by
Neuhofer et al. [39], data indicate that the regulation of the
Hsp70 promoter by ouabain is more complex than that of
Figure 7. UNBS1450 induces LMP-mediated cell death in human A549 NSCLC cells. Immunofluorescent staining for cathepsin B in untreated A549 cells (B; with A
representing the corresponding phase contrast image) in comparison with A549 cells treated for 15 hours with 10 nM UNBS1450 (D; with C representing the
corresponding phase contrast image).
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other TonEBP target genes. At present, we cannot give any
precise explanation on the relationship between TonEBP and
Hsp70, on one hand, and UNBS1450 action in human A549
NSCLCs, on the other hand. We will adopt a genomic and
proteomic approach to offer an explanation, however in-
complete, of this specific point. In addition, we have not yet
proven that UNBS1450 downregulates Hsp70 directly. An
assay based on Hsp70 overexpression may provide prom-
ising evidence—a strategy we are currently involved in. In-
deed, Nylandsted et al. [37] reported that the abrogation of
Hsp70 synthesis by the adenoviral transfer of a fragment of
Hsp70 cDNA resulted in extensive cell death in several
breast cancer cell lines, and that this cell death–associated
effect was clearly different from the standard apoptosis path-
way. In the present study, we also show that UNBS1450-
induced cell death is nonapoptotic. In using flow cytometry to
characterize the antiproliferative effects of UNBS1450 on
A549 NSCLC cells, we observed that this compound mark-
edly increased the percentage of A549 cells in the S phase of
the cell cycle and, to a lesser extent, in the G2 phase. We
then employed a dedicated microarray approach for the
preliminary characterization of UNBS1450-induced incre-
ment in S-phase A549 cells. These preliminary data suggest
that the UNBS1450-induced increase in S-phase A549 cells
could relate to a marked decrease in the mRNA levels of
cdc25B and cdc25C (data not shown). Kometiani et al. [49]
have shown that ouabain concentrations (100 nM or lower)
causing a < 25% inhibition in the pumping function of the
sodium pump have no effect on cell viability but do inhibit
proliferation. At the same concentrations, ouabain: 1) acti-
vates Src kinase and stimulates the interaction of Src and
Na+/K+ ATPase with the EGFR; 2) causes transient activa-
tion and then a sustained activation of extracellular signal–
regulated kinases 1 and 2 (ERK1/2); 3) increases the
expression of p21Cip1, but decreases that of p53; and 4)
activates c-Jun NH2-terminal kinase, but not p38 kinase [49].
Taken together, all these data suggest that ouabain-induced
activation/transactivation of Src/EGFR by the sodium pump
leads to the activation of ERK1/2, a resulting increase in the
level of cell cycle inhibitor p21Cip1, and growth arrest. We
are currently performing experiments to investigate whether
UNBS1450 has any similar effects on A549 NSCLC cells.
Hsp70 fulfils its prosurvival function by inhibiting LMP
[22–24,47], a perturbation of a lysosomal membrane func-
tion that leads to the release of lysosomal hydrolases (in-
cluding cathepsins) in the cell cytoplasm [22]. The marked
changes that occur in the lysosomal compartment during cell
transformation and the involvement of lysosomal enzymes in
death pathways that remain functional in advanced tumor
cells suggest that the lysosomal death pathway could con-
tribute significantly to programmed sensitivity to cell death
in cancer cells [23,24]. Furthermore, because LMP-induced
cell death is caspase- and apoptosis-independent, it is a very
interesting target in cancer therapy because it allows cell
death to occur even in cancer cells with multiple defects in
the normal apoptosis pathway. In this study, we show that
UNBS1450 induces LMP followed by a release of cathepsin
B in the A549 cell cytoplasm (Figures 6 and 7). The exact
mechanism by which Hsp70 inhibits LMP remains to be de-
ciphered. Because Hsp70 depletion from tumor cells—but
not from normal cells—triggers LMP, one might speculate
that Hsp70 is required for the stability of tumor-specific
subpopulations of lysosomes. In line with this, it is important
to note that Hsp70 is confined to endolysosomal membranes
in cancer cells and prevents both spontaneous and TNF-
and etoposide-induced LMP [22,47]. Furthermore, one cell-
related function already evidenced in Hsp70 is the facilitation
of the removal of injured proteins [50,51]. Thus, the protec-
tive Hsp70 effect could be due to the removal of toxic
proteins and protein aggregates.
Rosen et al. [52] recently reported that cardiac steroids
induce changes in endocytosis-dependent membrane traffic,
leading to the appearance of cytoplasmic vacuoles. These
authors report that a cardiac steroid– induced accumulation
of cytoplasmic membrane components is a result of inhibited
recycling within the late endocytic pathway [52].
In conclusion, through its interaction with the sodium
pump, UNBS1450 decreases the expression of Hsp70; this
likely leads to LMP and, thus, to overcoming of the multiple
anti–cell death mechanisms evidenced in NSCLCs, which
are at least partly responsible for the failure of currently used
chemotherapeutic drugs. UNBS1450 could thus be consid-
ered as a novel drug with a potential for NSCLC treatment.
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